Description of the intervention (study drugs)
malaria
MALARIA, CNS INFECTIONS, EMA
IPTsc aims to treat and prevent malaria infections in school-aged children. The practice requires the administration of a full treatment course of an anti-malarial medicine at regular intervals to these children [A fixed-dose combination (FDC) of DP (D-Artepp by Guillin Pharmaceuticals, China) has been approved by the European Medicines Agency (EMA). DP is registered by the Tanzania Medicines and Medical Devices Authority (TMDA) as an alternative drug for treatment of uncomplicated malaria. This drug is safe and efficacious at a body weight-associated dose of 60–73.9 mg/kg, given once daily over 3 days for uncomplicated malaria [